纳美芬治疗急性重度颅脑损伤疗效和安全性的系统评价

发布时间：2018-03-22 12:47

本文选题：纳美芬　切入点：急性重度颅脑损伤　出处：《中国药物应用与监测》2016年01期 　论文类型：期刊论文

【摘要】：目的:评价纳美芬治疗急性重度颅脑损伤(ASTBI)的疗效和安全性。方法:检索Pub Med、The Cochrane Library、Embase、CNKI、Wanfang、VIP、CBM等数据库,收集纳美芬治疗ASTBI的随机对照试验研究(RCTs),采用Rev Man 5.3和Stata11.0进行Meta分析和评价。结果:共纳入8项研究,共879例ASTBI患者。Meta分析结果显示:与对照组相比,纳美芬能降低ASTBI患者死亡率(P=0.03),提高总有效率(P0.000 1),并改善GCS评分(P0.000 01),同时可降低颅内压(P0.000 01)和提高GOS评分(P=0.002);亚组分析显示,无论与空白对照组,还是对照药品组比较,纳美芬均能明显提高总有效率(P=0.007,P=0.002);各项研究均未见明显药品不良反应。结论:纳美芬治疗ASTBI安全有效,鉴于本研究存在一定的局限性,且文献质量较低,其结论的可靠性仍需大样本、高质量的临床试验加以验证。
[Abstract]:Objective: to evaluate the efficacy and safety of namefen in the treatment of acute severe craniocerebral injury (ASTBI). A randomized controlled trial study of nalmefen in the treatment of ASTBI was carried out. Meta analysis and evaluation were performed with Rev Man 5.3 and Stata11.0. Results: a total of 879 ASTBI patients were included in the study. Meta-analysis showed that: compared with the control group, a total of 879 ASTBI patients were included in the study. Nalmefen could reduce the mortality rate of ASTBI patients, increase the total effective rate of P0. 0001g, and improve the GCS score (P0. 00001) and increase the GOS score (P0. 002). Subgroup analysis showed that, compared with the blank control group and the control drug group, the subgroup analysis showed that. Nalmefen could significantly improve the total effective rate of P0. 007 and P0. 002, and no significant adverse drug reactions were found in all studies. Conclusion: namefen is safe and effective in the treatment of ASTBI, because of the limitations of this study and the low quality of the literature, nalmefen is safe and effective in the treatment of ASTBI. The reliability of the conclusion still needs large sample, high-quality clinical trial to verify.
【作者单位】：宁波市鄞州区第二医院药剂科;宁波市鄞州区第二医院重症监护室;
【基金】：浙江省自然科学基金项目(LY14H300001)
【分类号】：R651.15

【参考文献】